Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

5.660 +0.080 (+1.43%)

Streaming Delayed Price Updated: 12:57 PM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9

...

27 28 Next >

The 15-Minute Breakthrough: A Deep Dive into GH Research (GHRS) and the Future of Rapid-Acting Psychedelics

March 26, 2026

Today’s Date: March 26, 2026 Introduction As the global mental health crisis reaches unprecedented levels, the pharmaceutical industry has been forced to look beyond traditional SSRIs toward more...

Via Finterra

Magic Mushrooms, Hard Cash: Compass Pathways’ Trial Win, Fast Raise ↗

February 20, 2026

Via MarketBeat

Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗

February 19, 2026

Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral.

Via Stocktwits

Topics ETFs Economy Government

CMPS Stock Climbs 5% In Premarket After FDA Clears PTSD Trial Path ↗

January 07, 2026

Via Stocktwits

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

CMPS Stock Slumps Premarket As $150M Offering Cuts Into Psychedelic Trial Buzz ↗

February 18, 2026

The company CMPS is planning to seek FDA guidance on a rolling review and target a New Drug Application submission in the fourth quarter.

Via Stocktwits

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

February 17, 2026

Via Chartmill

Why Did Compass Pathways Stock Rocket Higher Today? ↗

February 17, 2026

Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval.

Via The Motley Fool

Tuesday's session: gap up and gap down stocks ↗

February 17, 2026

Via Chartmill

Tuesday's pre-market session: top gainers and losers ↗

February 17, 2026

Via Chartmill

CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗

February 17, 2026

COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Via Stocktwits

CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗

February 17, 2026

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Via Stocktwits

Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗

December 24, 2025

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

Via Stocktwits

Topics ETFs

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 04, 2025

Via Benzinga

Compass (CMPS) Q2 Loss Improves 27% ↗

August 01, 2025

Via The Motley Fool

These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy? ↗

July 20, 2025

Via The Motley Fool

Stifel Says Compass Pathways Selloff 'Significantly Overdone' After Psilocybin Trial Data ↗

June 24, 2025

The company is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart.

Via Stocktwits

What's going on in today's session ↗

June 23, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Compass Pathways Stock Is Plunging Today: What's Going On? ↗

June 23, 2025

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 23, 2025

Via Benzinga

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts ↗

June 23, 2025

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Via Stocktwits

Crude Oil Falls 1%; US Services PMI Declines In June ↗

June 23, 2025

Via Benzinga

Which stocks are experiencing notable movement on Monday? ↗

June 23, 2025

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Why Is Compass Pathways Stock Trading Lower On Monday? ↗

June 23, 2025

Compass Pathways' COMP005 trial met its primary endpoint in TRD, but modest results sparked a 47% drop in shares amid investor disappointment

Via Benzinga

Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results ↗

June 23, 2025

Via Benzinga

Topics Stocks

These stocks are gapping in today's session ↗

June 23, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

Via Chartmill

These stocks are moving in today's pre-market session ↗

June 23, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 23, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 23, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

27 28 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.